| 产品编号 | bs-0096R |
| 英文名称 | AAT |
| 中文名称 | α-1抗胰蛋白酶抗体 |
| 别 名 | A1AT_HUMAN; Alpha-1-antitrypsin; SERPINA1; Alpha-1 protease inhibitor; Alpha-1-antiproteinase; Serpin A1;PI; PRO0684; PRO2209; serpin family A member 1; A1A; PI1; A1AT; nNIF; PRO2275; alpha1AT; |
 |
Specific References (1) | bs-0096R has been referenced in 1 publications.
[IF=3.06] Feng, Ya-Ling, et al. "Alpha-1-antitrypsin suppresses oxidative stress in preeclampsia by inhibiting the p38MAPK signaling pathway: An in vivo and in vitro study." PloS one 12.3 (2017): e0173711. IHC-P ; Mouse.
|
| 研究领域 | 心血管 免疫学 新陈代谢 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human,Rat (predicted: Mouse,Dog,Pig,Cow) |
| 产品应用 | IHC-P=1:100-500, IHC-F=1:100-500, ICC=1:100, IF=1:100-500, ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 44kDa |
| 细胞定位 | 细胞外基质 分泌型蛋白 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human alpha 1 Antitrypsin: 101-200/418 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Alpha-1-antitrypsin is a protease inhibitor, deficiency of which is associated with emphysema and liver disease. The protein is encoded by a gene (PI) located on the distal long arm of chromosome 14. Function: Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. Short peptide from AAT (SPAAT) is a reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE). Subcellular Location: Secreted. Short peptide from AAT: Secreted, extracellular space, extracellular matrix. Tissue Specificity: Plasma. Post-translational modifications: N-glycosylated. Differential glycosylation produces a number of isoforms. N-linked glycan at Asn-107 is alternatively di-antennary, tri-antennary or tetra-antennary. The glycan at Asn-70 is di-antennary with trace amounts of tri-antennary. Glycan at Asn-271 is exclusively di-antennary. Structure of glycans at Asn-70 and Asn-271 is Hex5HexNAc4. The structure of the antennae is Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc attached to the core structure Man(alpha1-6)[Man(alpha1-3)]Man(beta1-4)GlcNAc(beta1-4)GlcNAc. Some antennae are fucosylated, which forms a Lewis-X determinant. Proteolytic processing may yield the truncated form that ranges from Asp-30 to Lys-418. DISEASE: Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD) [MIM:613490]. A disorder whose most common manifestation is emphysema, which becomes evident by the third to fourth decade. A less common manifestation of the deficiency is liver disease, which occurs in children and adults, and may result in cirrhosis and liver failure. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age. Similarity: Belongs to the serpin family. SWISS: P01009 Gene ID: 5265 Database links: Entrez Gene: 5265 Human Omim: 107400 Human SwissProt: P01009 Human SwissProt: P07758 Mouse Unigene: 525557 Human α1-抗胰蛋白酶（A1AT）缺乏是最常见的遗传代谢病，能引起肺和肝的损伤。α1抗胰蛋白酶为呼吸系统的非特异性可溶因子，与呼吸道抵抗力关系密切，它可抑制多种酶的活性，包括细菌的酶，以及中性白细胞溶酶体分泌的蛋白酶、弹性蛋白酶、胶原酶、纤维蛋白溶酶和凝血酶。α1抗胰蛋白酶的缺乏与慢性阻塞性肺病的形成关系密切，因为它的缺乏，不能及时控制感染和炎症产生的多种蛋白酶，而造成肺组织破坏。 α1-抗胰蛋白酶由肝细胞产生,是一种分子量为45-56kDa的糖蛋白,它能抑制蛋白酶、弹性蛋白酶、胶原酶等多种水解酶的活性。 AAT也是一种糖蛋白，主要用于遗传性AAT缺乏症和良性恶性肝肿瘤、内胚窦瘤、组织细胞性淋巴瘤以及胰腺癌、胃癌、结肠癌等各种肿瘤的研究。此抗体与大、小鼠、狗和猪有交叉反应。 |
| 产品图片 |
Paraformaldehyde-fixed, paraffin embedded (Human kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (alpha 1 Antitrypsin) Polyclonal Antibody, Unconjugated (bs-0096R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining
Paraformaldehyde-fixed, paraffin embedded (Rat liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (alpha 1 Antitrypsin) Polyclonal Antibody, Unconjugated (bs-0096R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Human kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (alpha 1 Antitrypsin) Polyclonal Antibody, Unconjugated (bs-0096R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Human liver carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (alpha 1 Antitrypsin) Polyclonal Antibody, Unconjugated (bs-0096R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
